AIP
APTO

Almanack Investment Partners’s Aptose Biosciences, Inc. APTO Stock Holding History

Almanack Investment Partners’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7
Closed -$2K – 849
2022
Q3 		$2K Buy
+7
New +$2.41K ﹤0.01% 745

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
AC
Annandale Capital Dallas, Texas $709M AUM 11.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Almanack Investment Partners's APTO Position: Q4 2022 in Review

Almanack Investment Partners sold out of Aptose Biosciences, Inc. (APTO) in Q4 2022, closing a stake of 7 shares — an estimated $2K sold.

Almanack Investment Partners first reported a position in APTO in Q3 2022 and held it in 1 quarter. The position peaked at $2K in Q3 2022. 47 funds tracked by Wall St. Rank hold APTO as of Q4 2022.

  • Almanack Investment Partners reported no remaining Aptose Biosciences, Inc. position as of Q4 2022 after selling out during the quarter.
  • Almanack Investment Partners sold 7 Aptose Biosciences, Inc. shares in Q4 2022, an estimated $2K.
  • Almanack Investment Partners first reported a position in Aptose Biosciences, Inc. in Q3 2022 and held it in 1 quarter.
  • Almanack Investment Partners's Aptose Biosciences, Inc. position peaked at $2K in Q3 2022.
  • 47 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q4 2022.

Based on Almanack Investment Partners's 13F filing for Q4 2022, filed 9 Feb 2023.